Erin Schenk, MD, PhD, University of Colorado Cancer Center member, discusses the rapidly evolving treatment landscape in lung cancer.

Paul A. Bunn, Jr, MD, distinguished professor, James Dudley Chair in Lung Cancer Research, Division of Medical Oncology, University of Colorado, and a 2014 Giant of Cancer Care® in Lung Cancer, discusses potentially targeting HER3 in non–small cell lung cancer (NSCLC).

“Current guidelines recommend a 28-day course of enoxaparin for thromboprophylaxis after surgery for gynecologic cancer,” wrote Saketh R. Guntupalli, Director of the Division of Gynecologic Oncology, University of Colorado School of Medicine, and colleagues.

Paul A. Bunn, Jr, distinguished professor, James Dudley Chair in Lung Cancer Research, Division of Medical Oncology, University of Colorado and a 2014 Giant of Cancer Care® in Lung Cancer, highlights encouraging data with fam-trastuzumab deruxtecan-nxki (Enhertu) in HER2-mutant non–small cell lung cancer (NSCLC).

According to Kelly Faulk, University of Colorado Cancer Center investigator and pediatric oncologist at Children’s Hospital Colorado, these findings are not altogether negative. “Good treatments have been developed for some of our most common childhood cancers, such as acute lymphoblastic leukemia,” Faulk said in an interview with Healio.

On the CU Anschutz Medical Campus, there’s a factory known to churn out warriors, a fitness center just for patients battling cancer.

According to a study lead by Chad Rusthoven, MD, patients with small cell lung cancer (SCLC) with brain metastases saw similar if not slightly better survival when treated with stereotactic radiosurgery (SRS) compared with standard-of-care whole brain radiotherapy (WBRT).

“These outstanding results support rituximab as a new standard-of-care therapy for young patients with advanced B-cell non-Hodgkin lymphoma,” co-author Thomas Gross, of University of Colorado Cancer Center and Children’s Hospital Colorado, said.

Lung cancer is the leading cause of cancer deaths worldwide, and metastatic non–small cell lung cancer (NSCLC) is the deadliest form, with a 5-year survival rate of just over 5%. Nonetheless, thoracic oncologists at the University of Colorado Cancer Center in Aurora who specialize in the treatment of advanced NSCLC say there is room for optimism. In this six-part series, distinguished professor Paul Bunn and his colleagues Ross Camidge and Erin Schenk discuss how to choose the optimal treatment for a patient on the basis of pathologic findings, disease staging, and biomarker testing.

“Colorado has some of the highest UV exposure levels in the country,” Dr. Neil Box of the University of Colorado’s Cancer Center said during an interview on CBSN Denver. “Melanoma is historically the most dangerous form of cancer,” adding basal cell and squamous carcinoma are the most common types of skin cancer.